The document is a comprehensive analysis of the pharmaceutical sector in Kenya, prepared under the auspices of the World Bank Group. The report underscores the constitutional right of every Kenyan citizen to the highest attainable standard of health and wellness. It contextualizes the importance of a robust healthcare system, especially in light of global emergencies like the COVID-19 pandemic. The vision of Kenya, as outlined in its Vision 2030 and the Big 4 Agenda Programme, is to be a healthy, productive, and globally competitive nation. To achieve this, there's a recognized need for collaboration between the Ministry of Health and the Ministry of Industrialization, Trade and Enterprise Development. The objective is to bolster the local pharmaceutical manufacturing sector, which would not only create employment opportunities but also ensure access to quality medicines. The report acknowledges that Kenya has a plethora of laws and policies that can support its ambition to be a regional pharmaceutical manufacturing hub. These laws encompass various facets including health sector practices, tax incentives, intellectual property rights, environmental protection, and more. The document serves as a diagnostic tool, highlighting the potential, challenges, and pathways for the growth of the pharmaceutical industry in Kenya.
You can submit a specific query to QUAMED experts by clicking on the button below. We will send relevant answers directly to your mailbox.
Submit Query
The information provided on this Web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government.
ISO 9001:2015 - FS766975
© 2024 - QUAMED
Content of this site is licensed under a Creative Commons License- BY Attribution